Download PDF
Semin Thromb Hemost 2016; 42(08): 891-898
DOI: 10.1055/s-0036-1592305
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Update on the Treatment of Venous Thromboembolism

Sam Schulman
1   Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
20 October 2016 (online)

   Permissions and Reprints

Abstract

During the past 7 years, results from phase III trials comparing nonvitamin antagonist K oral anticoagulants (NOACs) with vitamin K antagonists (VKAs) or with placebo, including 34,900 patients, have been published. Recent guidelines have been updated and now suggest treatment with NOACs rather than with VKA. Other updates in the guidelines concern the initial thrombolytic treatment for selected patients with deep vein thrombosis or pulmonary embolism as well as the possibility of withholding anticoagulation for minimal venous thromboembolism. The optimal duration of anticoagulation after an unprovoked event is still debatable, depending on values and preferences assigned to recurrent thromboembolism versus bleeding complications. The choice is essentially between a short duration of 3 or perhaps 6 months for extensive thromboembolism and indefinite duration. Several clinical prediction rules have been developed to aid in this choice but they all address only the risk of recurrent thrombosis without weighing in the risk of bleeding. This review provides an update on recent systematic reviews, meta-analyses, and guidelines on the treatment of venous thromboembolism.

Keywords

venous thromboembolism - thrombolysis - anticoagulation - clinical prediction rules

Note

No funding was received for writing this review article.


 

  • References

  • 1 Wells PS, Anderson DR, Rodger M , et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000; 83 (3) 416-420
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Le Gal G, Righini M, Roy PM , et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 2006; 144 (3) 165-171
    CrossrefPubMedGoogle Scholar
  • 3 van Es N, van der Hulle T, van Es J , et al. Wells rule and D-dimer testing to rule out pulmonary embolism: a systematic review and individual-patient data meta-analysis. Ann Intern Med 2016; 165 (4) 253-261
    CrossrefPubMedGoogle Scholar
  • 4 Aujesky D, Obrosky DS, Stone RA , et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172 (8) 1041-1046
    CrossrefPubMedGoogle Scholar
  • 5 Jiménez D, Aujesky D, Moores L , et al; RIETE Investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170 (15) 1383-1389
    CrossrefPubMedGoogle Scholar
  • 6 Zondag W, Vingerhoets LM, Durian MF , et al; Hestia Study Investigators. Hestia criteria can safely select patients with pulmonary embolism for outpatient treatment irrespective of right ventricular function. J Thromb Haemost 2013; 11 (4) 686-692
    CrossrefPubMedGoogle Scholar
  • 7 Torbicki A, Perrier A, Konstantinides S , et al; ESC Committee for Practice Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29 (18) 2276-2315
    CrossrefPubMedGoogle Scholar
  • 8 Bova C, Sanchez O, Prandoni P , et al. Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. Eur Respir J 2014; 44 (3) 694-703
    CrossrefPubMedGoogle Scholar
  • 9 Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. Circulation 2006; 113 (4) 577-582
    CrossrefPubMedGoogle Scholar
  • 10 Jerjes-Sanchez C, Ramírez-Rivera A, Arriaga-Nava R , et al; de Lourdes García M. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis 1995; 2 (3) 227-229
    CrossrefPubMedGoogle Scholar
  • 11 Agnelli G, Becattini C. Acute pulmonary embolism. N Engl J Med 2010; 363 (3) 266-274
    CrossrefPubMedGoogle Scholar
  • 12 Kearon C, Akl EA, Ornelas J , et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149 (2) 315-352
    CrossrefPubMedGoogle Scholar
  • 13 Marti C, John G, Konstantinides S , et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J 2015; 36 (10) 605-614
    CrossrefPubMedGoogle Scholar
  • 14 Wang TF, Squizzato A, Dentali F, Ageno W. The role of thrombolytic therapy in pulmonary embolism. Blood 2015; 125 (14) 2191-2199
    CrossrefPubMedGoogle Scholar
  • 15 Meyer G, Vicaut E, Danays T , et al; PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014; 370 (15) 1402-1411
    CrossrefPubMedGoogle Scholar
  • 16 Elsharawy M, Elzayat E. Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis. A randomised clinical trial. Eur J Vasc Endovasc Surg 2002; 24 (3) 209-214
    CrossrefPubMedGoogle Scholar
  • 17 Enden T, Haig Y, Kløw NE , et al; CaVenT Study Group. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012; 379 (9810) 31-38
    CrossrefPubMedGoogle Scholar
  • 18 Sharifi M, Mehdipour M, Bay C, Smith G, Sharifi J. Endovenous therapy for deep venous thrombosis: the TORPEDO trial. Catheter Cardiovasc Interv 2010; 76 (3) 316-325
    CrossrefPubMedGoogle Scholar
  • 19 Du GC, Zhang MC, Zhao JC. Catheter-directed thrombolysis plus anticoagulation versus anticoagulation alone in the treatment of proximal deep vein thrombosis - a meta-analysis. Vasa 2015; 44 (3) 195-202
    CrossrefPubMedGoogle Scholar
  • 20 Qayyum F, Holbrook A, Lam J, Kovacs MJ, Schulman S. Should vitamin K antagonist therapy be started simultaneously with parenteral anticoagulation: a meta-analysis?. Blood Coagul Fibrinolysis 2012; 23 (8) 705-713
    CrossrefPubMedGoogle Scholar
  • 21 Agnelli G, Buller HR, Cohen A , et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (9) 799-808
    CrossrefPubMedGoogle Scholar
  • 22 Bauersachs R, Berkowitz SD, Brenner B , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 23 Büller HR, Prins MH, Lensin AW , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedGoogle Scholar
  • 24 Schulman S, Kakkar AK, Goldhaber SZ , et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 (7) 764-772
    CrossrefPubMedGoogle Scholar
  • 25 Schulman S, Kearon C, Kakkar AK , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 26 Büller HR, Décousus H, Grosso MA , et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 27 Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database Syst Rev 2015; (6) CD010956
    PubMedGoogle Scholar
  • 28 Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Cochrane Database Syst Rev 2015; (12) CD010957
    PubMedGoogle Scholar
  • 29 van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124 (12) 1968-1975
    CrossrefPubMedGoogle Scholar
  • 30 Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36 (2) 386-399
    CrossrefPubMedGoogle Scholar
  • 31 Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009; 37 (5) 1056-1064
    CrossrefPubMedGoogle Scholar
  • 32 Zhang D, Frost CE, He K , et al. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Drug Metab Dispos 2013; 41 (4) 906-915
    CrossrefPubMedGoogle Scholar
  • 33 Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc 2014; 62 (5) 857-864
    CrossrefPubMedGoogle Scholar
  • 34 Schulman S, Eriksson H, Goldhaber SZ , et al. Influence of renal function on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-Cover and RE-Cover II. Blood 2013; 122: 212
    PubMedGoogle Scholar
  • 35 van der Hulle T, den Exter PL, van den Hoven P , et al. Cohort study on the management of cancer-associated venous thromboembolism aimed at the safety of stopping anticoagulant therapy in patients cured of cancer. Chest 2016; 149 (5) 1245-1251
    CrossrefPubMedGoogle Scholar
  • 36 Prandoni P, Villalta S, Bagatella P , et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997; 82 (4) 423-428
    PubMedGoogle Scholar
  • 37 Lopes LC, Spencer FA, Neumann I , et al. Bleeding risk in atrial fibrillation patients taking vitamin K antagonists: systematic review and meta-analysis. Clin Pharmacol Ther 2013; 94 (3) 367-375
    CrossrefPubMedGoogle Scholar
  • 38 Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152 (9) 578-589
    CrossrefPubMedGoogle Scholar
  • 39 McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 2006; 368 (9533) 371-378
    CrossrefPubMedGoogle Scholar
  • 40 Kearon C, Spencer FA, O'Keeffe D , et al; D-dimer Optimal Duration Study Investigators. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med 2015; 162 (1) 27-34
    CrossrefPubMedGoogle Scholar
  • 41 Prandoni P, Lensing AW, Prins MH , et al. The impact of residual thrombosis on the long-term outcome of patients with deep venous thrombosis treated with conventional anticoagulation. Semin Thromb Hemost 2015; 41 (2) 133-140
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Cosmi B, Legnani C, Iorio A , et al; PROLONG Investigators (on behalf of FCSA, Italian Federation of Anticoagulation Clinics). Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. Eur J Vasc Endovasc Surg 2010; 39 (3) 356-365
    CrossrefPubMedGoogle Scholar
  • 43 Carrier M, Rodger MA, Wells PS, Righini M, LE Gal G. Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost 2011; 9 (6) 1119-1125
    CrossrefPubMedGoogle Scholar
  • 44 Donadini MP, Ageno W, Antonucci E , et al. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. Thromb Haemost 2014; 111 (1) 172-179
    PubMedGoogle Scholar
  • 45 Tosetto A, Iorio A, Marcucci M , et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012; 10 (6) 1019-1025
    CrossrefPubMedGoogle Scholar
  • 46 Tritschler T, Méan M, Limacher A, Rodondi N, Aujesky D. Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model. Blood 2015; 126 (16) 1949-1951
    CrossrefPubMedGoogle Scholar
  • 47 Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010; 121 (14) 1630-1636
    CrossrefPubMedGoogle Scholar
  • 48 Rodger MA, Kahn SR, Wells PS , et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179 (5) 417-426
    CrossrefPubMedGoogle Scholar
  • 49 Ensor J, Riley RD, Jowett S , et al; PIT-STOP collaborative group. Prediction of risk of recurrence of venous thromboembolism following treatment for a first unprovoked venous thromboembolism: systematic review, prognostic model and clinical decision rule, and economic evaluation. Health Technol Assess 2016; 20 (12) i-xxxiii , 1–190
    PubMedGoogle Scholar
  • 50 De Martino RR, Wallaert JB, Rossi AP, Zbehlik AJ, Suckow B, Walsh DB. A meta-analysis of anticoagulation for calf deep venous thrombosis. J Vasc Surg 2012; 56 (1) 228-37.e1 , discussion 236–237
    CrossrefPubMedGoogle Scholar
  • 51 Carrier M, Righini M, Wells PS , et al. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost 2010; 8 (8) 1716-1722
    CrossrefPubMedGoogle Scholar
  • 52 Schulman S, Lindmarker P, Holmström M , et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 4 (4) 734-742
    CrossrefPubMedGoogle Scholar
  • 53 Schulman S. Getting intimate with the venous thrombus. J Thromb Haemost 2009; 7 (8) 1266-1267
    CrossrefPubMedGoogle Scholar
  • 54 Kahn SR, Shapiro S, Wells PS , et al; SOX trial investigators. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet 2014; 383 (9920) 880-888
    CrossrefPubMedGoogle Scholar
  • 55 Kahn SR, Shapiro S, Ducruet T , et al. Graduated compression stockings to treat acute leg pain associated with proximal DVT. A randomised controlled trial. Thromb Haemost 2014; 112 (6) 1137-1141
    CrossrefPubMedGoogle Scholar
  • 56 Eichinger S, Heinze G, Kyrle PA. D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. J Am Heart Assoc 2014; 3 (1) e000467
    CrossrefPubMedGoogle Scholar